Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic TNBC
NCT05522491Phase 2Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Sep 2026
- Primary completion
- Sep 2030
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of olaparib in triple-negative breast cancer (TNBC), sponsored by The Fourth Hospital of Hebei Medical University. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
olaparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05522491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05522491.